Bionoid Pharma Inc.
BINP
$0.08
$0.000.00%
OTC PK
| 03/31/2012 | 03/31/2011 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | 44.00% | |||
| Gross Profit | -- | -44.00% | |||
| SG&A Expenses | -- | 200.66% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -- | 200.29% | |||
| Operating Income | -- | -200.29% | |||
| Income Before Tax | -- | -163.33% | |||
| Income Tax Expenses | -- | 244.44% | |||
| Earnings from Continuing Operations | -- | -163.35% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -- | -163.35% | |||
| EBIT | -- | -200.29% | |||
| EBITDA | -- | -203.16% | |||
| EPS Basic | -- | -314.86% | |||
| Normalized Basic EPS | -- | -314.95% | |||
| EPS Diluted | -- | -314.86% | |||
| Normalized Diluted EPS | -- | -314.95% | |||
| Average Basic Shares Outstanding | -- | 147.37% | |||
| Average Diluted Shares Outstanding | -- | 147.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||